All In Biotech

Investigational drug · Phase 3

Atigotatug+Nivolumab

Also called: BMS-986489

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Extensive-Stage Small Cell Lung Cancer.

Phase 3

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

3

Any phase or sponsor naming "Atigotatug+Nivolumab"

First trial start

2025

Feb 25, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Atigotatug+Nivolumab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Extensive-Stage Small Cell Lung Cancer

Approved drugs for the same conditions: Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Atigotatug+Nivolumab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 1 on PubMed

Also in development for Extensive-Stage Small Cell Lung Cancer

  • QLC5508MHB088CPhase 39 trials

    Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma

  • BMS-986012Phase 21 trial

    Bristol Myers Squibb · Extensive-stage Small Cell Lung Cancer

  • ECI830Phase 21 trial

    Novartis · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Bristol Myers Squibb.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.